Pharmacology of Adenosine Receptors: Recent Advancements
Biomolecules · 14.09.2023 · 13 (9) · 1387
DOI: 10.3390/biom13091387 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 14.09.2023. Verfasst von Fabrizio Vincenzi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy. Hauptthemen laut MEDLINE: Receptors, Purinergic P1, Purinergic P1 Receptor Antagonists. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research (MUR), Ministry of University and Research (MUR) National Recovery and Resilience Plan (NRRP).
Abstract (Originalsprache)
Adenosine receptors (ARs) are widely acknowledged pharmacological targets yet are still underutilized in clinical practice. Their ubiquitous distribution in almost all cells and tissues of the body makes them, on the one hand, excellent candidates for numerous diseases, and on the other hand, intrinsically challenging to exploit selectively and in a site-specific manner. This review endeavors to comprehensively depict the substantial advancements witnessed in recent years concerning the development of drugs that modulate ARs. Through preclinical and clinical research, it has become evident that the modulation of ARs holds promise for the treatment of numerous diseases, including central nervous system disorders, cardiovascular and metabolic conditions, inflammatory and autoimmune diseases, and cancer. The latest studies discussed herein shed light on novel mechanisms through which ARs exert control over pathophysiological states. They also introduce new ligands and innovative strategies for receptor activation, presenting compelling evidence of efficacy along with the implicated signaling pathways. Collectively, these emerging insights underscore a promising trajectory toward harnessing the therapeutic potential of these multifaceted targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.
- University of Ferrara, 44121 Ferrara, Italy.
ORCID-Profile: Fabrizio Vincenzi, Silvia Pasquini, Chiara Contri, Stefania Merighi, Katia Varani
Förderung
- Italian Ministry of University and Research (MUR)
- Ministry of University and Research (MUR) National Recovery and Resilience Plan (NRRP)
Zitieren
APA
Vincenzi, F., Pasquini, S., Contri, C., Cappello, M., Nigro, M., Travagli, A., Merighi, S., Gessi, S., Borea, P. A., & Varani, K. (2023). Pharmacology of Adenosine Receptors: Recent Advancements. Biomolecules, 13(9), 1387. https://doi.org/10.3390/biom13091387
Vancouver
Vincenzi F, Pasquini S, Contri C, Cappello M, Nigro M, Travagli A, et al. Pharmacology of Adenosine Receptors: Recent Advancements. Biomolecules. 2023;13(9):1387. doi:10.3390/biom13091387
BibTeX
@article{Vincenzi2023,
author = {Vincenzi, Fabrizio and Pasquini, Silvia and Contri, Chiara and Cappello, Martina and Nigro, Manuela and Travagli, Alessia and Merighi, Stefania and Gessi, Stefania and Borea, Pier Andrea and Varani, Katia},
title = {Pharmacology of Adenosine Receptors: Recent Advancements},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {9},
pages = {1387},
doi = {10.3390/biom13091387}
}
EUVIMED